Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and
neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

Corlieve Therapeutics

Lava Therapeutics

Acrivon Therapeutics

Pureos Bioventures

Our portfolio company VICO Therapeutics B.V. closed their Series B financing of EUR 54mn to advance the clinical development of their lead program VO659 in spinocerebellar ataxia types 3 and 1 and Huntington’s disease.
Congratulations to the team!
 
We are looking forward continuing the journey to bring innovation to patients with rare neurological disease.

https://lnkd.in/eiQ2xBX4

Our portfolio company LAVA Therapeutics N.V. announces a collaboration with Merck & Co., Inc. to evaluate Lava-1207 in combination with pembrolizumab. This cooperation will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with prostate cancer (mCRPC).
We are looking forward continuing the journey to bring new therapies to patients with mCRPC.

https://lnkd.in/eBNc9ZjA 

Pureos Bioventures portfolio company AM-Pharma started testing ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage in a clincal Phase 2 study. A high medical need indication. Fingers crossed that ilofotase will help to prevent CSA-RD!

https://lnkd.in/eykpXE5R

Start your year with listening to the latest episode of The Drug Discovery World Podcast! Manfred Ruediger, CEO of our portfolio company Ariceum Therapeutics talks about their pipeline of radiopharmaceutical drugs for cancer patients and the future for the company.
 
Do not miss:
https://lnkd.in/eGcPJwGK

Google Font API

HSTS

Content Delivery Network

nginx

Google Universal Analytics

CrUX Dataset

CrUX Top 50m

Pound Sterling

CloudFront

PostalAddress Schema

Martin Münchbach

Managing Partner & Founding Partner

Ximing Ding

Investment Manager

Klaus Breiner

Managing Partner & Founding partner

Dominik Escher

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.

Corlieve Therapeutics is a biotechnology company.

Investors Active in European Union (EU) (Top 10K)

Venture Capital Investors with Investments in Berlin

Venture Capital Investors with Investments in Paris, Ile-de-France

Europe Investors (Top 10K)

Pureos Bioventures is a new venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats

BB Pureos Bioventures LP

Advertising, Business and Retail Services

Küsnacht

Zurich

Switzerland

Europe

Alentis Therapeutics–Bellevue: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor BB Pureos

Iceland

Israel

Asia

Poland

United Kingdom

Nigeria

Africa

Fierce Biotech Fundraising Tracker is a platform that tracks venture capital flowing into the biotech industry, providing insights into the investment landscape.

Fierce Biotech Fundraising Tracker

Excedr offers top accelerator programs for biotech startups, providing support and resources to bring innovative biotech companies to market.

Excedr Biotech Accelerators

Shizune is a platform that lists 50 VC funds investing in biotech startups based in Switzerland, ranking investors based on the number of investments they make.

Shizune Biotech VC Funds Switzerland

Pureos Bioventures is a venture capital firm that focuses on early-stage investments in the life sciences sector, particularly in therapeutic start-ups developing innovative treatments for serious diseases.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 10, 2024 11:06 PM	1b2f9d9e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	019ff12b
crunchbase profile	general	Nov 19, 2024 2:01 AM	19c4f496
li profile	general	May 10, 2024 11:06 PM	88edb524
translate crunchbase fundingrounds	general	Nov 19, 2024 2:33 AM	51bccaee
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PUREOSBIO

Pureos Bioventures